Literature DB >> 30411380

The Epidermal Growth Factor Receptor Ligand Amphiregulin Protects From Cholestatic Liver Injury and Regulates Bile Acids Synthesis.

Eva Santamaría1,2, Carlos M Rodríguez-Ortigosa1,2,3, Iker Uriarte1,2, Maria U Latasa1, Raquel Urtasun1, Gloria Alvarez-Sola1, Marina Bárcena-Varela1, Leticia Colyn1, Sara Arcelus1, Maddalen Jiménez1, Kathleen Deutschmann4, Ana Peleteiro-Vigil5, Julian Gómez-Cambronero6, Malgorzata Milkiewicz7, Piotr Milkiewicz8,9, Bruno Sangro2,3,10, Verena Keitel4, Maria J Monte2,5, Jose J G Marin2,5, Maite G Fernández-Barrena1,2, Matias A Ávila1,2,3, Carmen Berasain1,2,3.   

Abstract

Intrahepatic accumulation of bile acids (BAs) causes hepatocellular injury. Upon liver damage, a potent protective response is mounted to restore the organ's function. Epidermal growth factor receptor (EGFR) signaling is essential for regeneration after most types of liver damage, including cholestatic injury. However, EGFR can be activated by a family of growth factors induced during liver injury and regeneration. We evaluated the role of the EGFR ligand, amphiregulin (AREG), during cholestatic liver injury and regulation of AREG expression by BAs. First, we demonstrated increased AREG levels in livers from patients with primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC). In two murine models of cholestatic liver injury, bile duct ligation (BDL) and alpha-naphthyl-isothiocyanate (ANIT) gavage, hepatic AREG expression was markedly up-regulated. Importantly, Areg-/- mice showed aggravated liver injury after BDL and ANIT administration compared to Areg+/+ mice. Recombinant AREG protected from ANIT and BDL-induced liver injury and reduced BA-triggered apoptosis in liver cells. Oral BA administration induced ileal and hepatic Areg expression, and, interestingly, cholestyramine feeding reduced postprandial Areg up-regulation in both tissues. Most interestingly, Areg-/- mice displayed high hepatic cholesterol 7 α-hydroxylase (CYP7A1) expression, reduced serum cholesterol, and high BA levels. Postprandial repression of Cyp7a1 was impaired in Areg-/- mice, and recombinant AREG down-regulated Cyp7a1 mRNA in hepatocytes. On the other hand, BAs promoted AREG gene expression and protein shedding in hepatocytes. This effect was mediated through the farnesoid X receptor (FXR), as demonstrated in Fxr-/- mice, and involved EGFR transactivation. Finally, we show that hepatic EGFR expression is indirectly induced by BA-FXR through activation of suppressor of cytokine signaling-3 (SOC3).
Conclusion: AREG-EGFR signaling protects from cholestatic injury and participates in the physiological regulation of BA synthesis.
© 2018 by the American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30411380     DOI: 10.1002/hep.30348

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  10 in total

1.  Amphiregulin Aggravates Glomerulonephritis via Recruitment and Activation of Myeloid Cells.

Authors:  Simon Melderis; Julia Hagenstein; Matthias Tobias Warkotsch; Julien Dang; Georg Rudolf Herrnstadt; Christoph Benjamin Niehus; Katrin Neumann; Ulf Panzer; Carmen Berasain; Matias A Avila; Pierre-Louis Tharaux; Gisa Tiegs; Oliver M Steinmetz
Journal:  J Am Soc Nephrol       Date:  2020-07-02       Impact factor: 10.121

2.  Deficiency of inactive rhomboid protein 2 (iRhom2) attenuates diet-induced hyperlipidaemia and early atherogenesis.

Authors:  Carmen Hannemann; Johannes H Schecker; Alica Brettschneider; Jana Grune; Nicole Rösener; Andrea Weller; Verena Stangl; Edward A Fisher; Karl Stangl; Antje Ludwig; Bernd Hewing
Journal:  Cardiovasc Res       Date:  2022-01-07       Impact factor: 10.787

Review 3.  Insights Into Human Intrahepatic NK Cell Function From Single Cell RNA Sequencing Datasets.

Authors:  Gráinne Jameson; Mark W Robinson
Journal:  Front Immunol       Date:  2021-03-22       Impact factor: 7.561

Review 4.  Regulation of Fibrotic Processes in the Liver by ADAM Proteases.

Authors:  Dirk Schmidt-Arras; Stefan Rose-John
Journal:  Cells       Date:  2019-10-09       Impact factor: 6.600

5.  Downregulation of Epidermal Growth Factor Receptor in hepatocellular carcinoma facilitates Transforming Growth Factor-β-induced epithelial to amoeboid transition.

Authors:  Judit López-Luque; Esther Bertran; Eva Crosas-Molist; Oscar Maiques; Andrea Malfettone; Laia Caja; Teresa Serrano; Emilio Ramos; Victoria Sanz-Moreno; Isabel Fabregat
Journal:  Cancer Lett       Date:  2019-08-26       Impact factor: 8.679

6.  Dual Pharmacological Targeting of HDACs and PDE5 Inhibits Liver Disease Progression in a Mouse Model of Biliary Inflammation and Fibrosis.

Authors:  Alex Claveria-Cabello; Leticia Colyn; Iker Uriarte; Maria Ujue Latasa; Maria Arechederra; Jose M Herranz; Laura Alvarez; Jesus M Urman; Maria L Martinez-Chantar; Jesus M Banales; Bruno Sangro; Krista Rombouts; Julen Oyarzabal; Jose J G Marin; Carmen Berasain; Matias A Avila; Maite G Fernandez-Barrena
Journal:  Cancers (Basel)       Date:  2020-12-13       Impact factor: 6.639

7.  Arbutin Alleviates the Liver Injury of α-Naphthylisothiocyanate-induced Cholestasis Through Farnesoid X Receptor Activation.

Authors:  Peijie Wu; Ling Qiao; Han Yu; Hui Ming; Chao Liu; Wenjun Wu; Baixue Li
Journal:  Front Cell Dev Biol       Date:  2021-12-02

8.  Network Proximity-Based Drug Repurposing Strategy for Early and Late Stages of Primary Biliary Cholangitis.

Authors:  Endrit Shahini; Giuseppe Pasculli; Andrea Mastropietro; Paola Stolfi; Paolo Tieri; Davide Vergni; Raffaele Cozzolongo; Francesco Pesce; Gianluigi Giannelli
Journal:  Biomedicines       Date:  2022-07-13

9.  The effect of serum IL-2 levels on the prognosis of primary biliary cholangitis-related liver failure and the preliminary exploration of its mechanism.

Authors:  Qi Wang; Yang Wang; Wenying Qiao; Bin Xu; Yanmin Liu; Xiaodan Zhang; Wenjuan Li; Juan Zhao; Mengcheng Liu; Yang Zhang; Dexi Chen; Chunyang Huang; Ronghua Jin
Journal:  Front Immunol       Date:  2022-09-08       Impact factor: 8.786

10.  Biliary NIK promotes ductular reaction and liver injury and fibrosis in mice.

Authors:  Zhiguo Zhang; Xiao Zhong; Hong Shen; Liang Sheng; Suthat Liangpunsakul; Anna S Lok; M Bishr Omary; Shaomeng Wang; Liangyou Rui
Journal:  Nat Commun       Date:  2022-08-30       Impact factor: 17.694

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.